AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
RegulatoryapprovedTEPKINLYlenalidomiderituximabPositive
AI Analysis
Summary
AbbVie announced European Commission approval of TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab for relapsed or refractory follicular lymphoma, marking the first bispecific-based therapy approved in Europe for this indication in the second-line setting as a chemotherapy-free option.
Clinical Trial Data
Phase
Phase 3
Outcome Details
European Commission approval for epcoritamab in combination with lenalidomide and rituximab for relapsed or refractory follicular lymphoma in second-line setting
Importance:8/10
Sentiment:
0.90
regulatory approvalEuropean Commissiononcologylymphomabispecific antibodychemotherapy-freecombination therapy
Related Companies
Read the original article
Published by PR Newswire Biotech on July 6, 2026 5:45 PM